Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.060 +0.030 (+0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Is the Market Bullish or Bearish on Recursion Pharmaceuticals?
Via Benzinga
Capital Flows Shift From Research Labs to Pharmacy Counters-A Watershed Moment for AI Health
Issued on behalf of Avant Technologies Inc. Vancouver, BC – June 17, 2025 – USA News Commentary – Momentum continues to build behind AI in healthcare, as capital finds its way to technologies capable... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts
Via Benzinga
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence Intellectual Property
Earnings Scheduled For May 5, 2025
Via Benzinga
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
Via The Motley Fool
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway. 
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead
The company now expects its projected cash runway to extend into the fourth quarter of 2027. 
Via Stocktwits
Topics Artificial Intelligence Workforce
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
Via Benzinga
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT
Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict... 
Via Benzinga
Topics Artificial Intelligence
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
A handful of industries are on the verge of explosive growth. These three companies are poised to gain the most. 
Via The Motley Fool
Topics Energy
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
While institutional money managers have released their Q1 holdings, so has the heart and soul of the AI revolution, NVIDIA. See which six stocks NVIDIA owns. 
Via MarketBeat
Topics Artificial Intelligence Earnings
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Why Recursion Pharmaceuticals Stock Is Plummeting Today
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
Via The Motley Fool
Topics Artificial Intelligence
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data
Traders flagged a key technical level at $4.65 and raised concerns over an outlier patient in the Tupelo trial, with attention now turning to management’s commentary during the earnings call. 
Via Stocktwits
Topics Earnings
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
How Do Investors Really Feel About Recursion Pharmaceuticals?
Via Benzinga
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.